US Patent No: 8,067,022 - Analytics, PDF, Full Text and PAIR Access

Number of patents in Portfolio can not be more than 2000

Therapeutic inhibitor of vascular smooth muscle cells

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BOSTON SCIENTIFIC SCIMED, INC.MAPLE GROVE, MN4906

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Anderson, Peter G Birmingham, US 15 1057
Kunz, Lawrence L Sammamish, US 29 2477

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (28)
4,487,780 Method of treatment of rheumatoid arthritis 23 1982
4,613,665 Process for covalent coupling for the production of conjugates, and polysaccharide containing products thereby obtained 146 1983
4,678,466 Internal medication delivery method and vehicle 37 1985
4,840,939 Treatment of cancer with phlorizin and its derivatives 30 1987
4,824,436 Method for the prevention of restenosis 259 1987
4,853,377 Method and composition for increasing production of serotonin 17 1988
5,002,531 Dilation catheter with an inflatable balloon 192 1988
4,968,350 Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase, the resulting powder and utilization thereof 42 1988
5,199,939 Radioactive catheter 276 1990
5,040,548 Angioplasty mehtod 470 1990
5,061,273 Angioplasty apparatus facilitating rapid exchanges 554 1990
5,163,952 Expandable polymeric stent with memory and delivery apparatus and method 676 1990
5,180,366 Apparatus and method for angioplasty and for preventing re-stenosis 196 1990
5,232,444 Dilatation catheter 323 1991
5,216,021 Analgesic method 11 1991
5,258,020 Method of using expandable polymeric stent with memory 331 1992
5,288,735 Treatment of glaucoma 26 1992
5,342,348 Method and device for treating and enlarging body lumens 507 1992
5,451,233 Angioplasty apparatus facilitating rapid exchanges 322 1994
5,470,876 Topical sod for treating hair loss 27 1994
5,470,883 Method of treating peripheral vasoconstriction with tamoxifen citrate 33 1994
5,693,607 Uses of TGF-.beta. receptor fragment as a therapeutic agent 26 1994
5,541,174 Analgesic method 13 1995
5,521,171 Anti-inflammatory and anti-ulcer compounds and process 11 1995
5,639,274 Integrated catheter system for balloon angioplasty and stent delivery 223 1995
5,749,888 Method of using angioplasty apparatus facilitating rapid exchanges 78 1995
6,575,993 Angioplasty apparatus facilitating rapid exchanges 105 1995
6,036,715 Angioplasty apparatus facilitating rapid exchanges 128 1997
 
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (1)
5,189,212 Triarylethylene carboxylic acids with estrogenic activity 87 1990
 
International Copper Research Association, Inc. (3)
4,670,428 Method for treating convulsions and epilepsy with organic copper compounds 12 1984
4,657,928 Organic copper complexes as radioprotectants 15 1984
4,952,607 Copper complex for treating cancer 17 1986
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (2)
6,476,200 Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion 4 1994
6,492,106 Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion 5 1994
 
MITSUBISHI PETROCHEMICAL COMPANY LIMITED (1)
4,705,647 Copper-type conductive coating composition 23 1986
 
ALKERMES CONTROLLED THERAPEUTICS INC. II (2)
4,389,330 Microencapsulation process 317 1980
4,732,763 Active/passive immunization of the internal female reproductive organs 69 1984
 
Pharmasonics, Inc. (1)
6,210,393 Methods and systems for the inhibition of vascular hyperplasia 104 1998
 
GLAXO WELLCOME INC. (1)
5,681,835 Non-steroidal ligands for the estrogen receptor 32 1994
 
WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, THE, 36TH AND SPRUCE STREETS, PHILADELPHIA, PA 19104 A CORP OF PA (1)
4,664,097 Nuclear transplantation in the mammalian embryo by microsurgery and cell fusion 15 1984
 
PEPSICO, INC. (1)
4,835,002 Microemulsions of oil in water and alcohol 104 1987
 
Noven Pharmaceuticals, Inc. (3)
5,234,957 Compositions and methods for topical administration of pharmaceutically active agents 154 1991
5,332,576 Compositions and methods for topical administration of pharmaceutically active agents 114 1993
5,446,070 Compositions and methods for topical administration of pharmaceutically active agents 235 1993
 
DRAXIMAGE, INC. (1)
5,248,764 Chelate derivatives of atrial natriuretic factor (ANF) 51 1992
 
PONIARD PHARMACEUTICALS, INC. (9)
5,847,007 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells 21 1994
5,472,985 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells 43 1994
5,545,569 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells 59 1995
5,595,722 Method for identifying an agent which increases TGF-beta levels 85 1995
5,770,609 Prevention and treatment of cardiovascular pathologies 99 1995
5,599,844 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells 49 1995
5,773,479 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells 33 1995
5,945,456 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells 36 1997
6,251,920 Prevention and treatment of cardiovascular pathologies 15 1998
 
KASINKAS, MICHAEL (1)
5,053,033 Inhibition of restenosis by ultraviolet radiation 263 1990
 
Medical Innovative Technologies R&D Limited Partnership (2)
5,059,166 Intra-arterial stent with the capability to inhibit intimal hyperplasia 457 1989
5,176,617 Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct 244 1991
 
Heumann Pharma GmbH (1)
4,973,755 Stable solvent adducts of Z-1-(p-.beta.-dimethylaminoethoxy-phenyl)-1-(p-hydroxyphenyl)-2-phenyl-but-1-ene 31 1988
 
YEDA RESEARCH AND DEVELOPMENT CO. LTD. (1)
4,996,194 Pressure treated autoimmune specific T cell compositions 14 1986
 
Warner-Lambert Company (1)
5,516,807 Method for treating vascular proliferative disorders following balloon angioplasty 35 1994
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
4,839,155 Iodotamoxifen derivatives and use for estrogen receptor-positive breast cancer detection and therapy 46 1987
 
COR THERAPEUTICS, INC. (1)
5,268,358 PDGF receptor blocking peptides 59 1991
 
UBE INDUSTRIES, LTD. (1)
4,872,867 Compositions having antithrombogenic properties and blood contact medical devices using the same 128 1989
 
AMS Medinvent S.A. (2)
4,655,771 Prosthesis comprising an expansible or contractile tubular body 1574 1983
5,061,275 Self-expanding prosthesis 729 1989
 
CID S.P.A. (2)
6,309,414 Angioplasty stents 178 1997
6,616,690 Angioplasty stents 52 2001
 
COLLAGEN AESTHETICS, INC. (2)
5,292,802 Collagen-polymer tubes for use in vascular surgery 174 1992
5,308,889 Dehydrated collagen-polymer strings 166 1992
 
HEMODYNAMICS, INC. (1)
5,474,563 Cardiovascular stent and retrieval apparatus 213 1994
 
EBOC, Inc. (1)
5,411,988 Compositions and methods for inhibiting inflammation and adhesion formation 71 1993
 
Whitehead Institute for Biomedical Research (1)
6,544,790 Reverse transfection method 60 2000
 
Cytogen Corporation (1)
4,867,973 Antibody-therapeutic agent conjugates 192 1984
 
Rhone-Poulenc Chimie (1)
5,356,713 Magnetizable composite microspheres of hydrophobic crosslinked polymer, process for preparing them and their application in biology 62 1993
 
MARYLAND BIOPOLYMER TECHNOLOGIES, LLC (1)
5,512,055 Anti-infective and anti-inflammatory releasing systems for medical devices 246 1994
 
MERRELL DOW PHARMACEUTICALS INC. (1)
5,460,807 Antiproliferative oligomers 26 1993
 
XEROX CORPORATION (5)
4,744,981 Trichothecene antibody conjugates 42 1985
4,879,225 Enhanced production of antibodies utilizing insolubilized immune complexes 27 1987
4,897,255 Metal radionuclide labeled proteins for diagnosis and therapy 122 1987
4,906,452 Trichothecene conjugates and methods of use 30 1988
5,066,789 Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages 40 1989
 
MOBIL OIL CORPORATION (1)
4,401,554 Split stream reforming 38 1982
 
Comedicus Incorporated (1)
5,650,447 Nitric oxide-releasing polymers to treat restenosis and related disorders 79 1994
 
BISACCIA & KLAINER, INC. (1)
5,284,869 Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty 30 1991
 
THOMAS JEFFERSON UNIVERSITY (1)
6,133,242 Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes 27 1995
 
VISIONEX, INC (1)
4,997,652 Biodegradable ocular implants 243 1989
 
University of Kentucky Research Foundation (1)
5,378,475 Sustained release drug delivery devices 225 1991
 
SUDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURT (1)
6,093,221 Process for reducing sulfur and vat dyes 3 1999
 
E.R. SQUIBB & SONS, INC. (2)
5,140,012 Method for preventing onset of restenosis after angioplasty employing pravastatin 52 1990
5,166,143 Method for preventing onset of restenosis after angioplasty employing an ace inhibitor 35 1991
 
STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (1)
5,324,739 Compound exhibiting antiproliferative activity against cells 21 1993
 
AMERICAN BIOSCIENCE, INC. (1)
5,362,478 Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell 158 1993
 
WAYNE STATE UNIVERSITY (1)
5,199,951 Method of drug application in a transporting medium to an arterial wall injured during angioplasty 136 1991
 
3M INNOVATIVE PROPERTIES COMPANY (1)
6,198,016 Wet skin adhesive article 41 1999
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (2)
4,605,644 Method for stimulating recovery from ischemia employing ribose and adenine 57 1985
5,030,637 Anisodamine to prevent and treat eye disease 9 1990
 
LION CORPORATION (1)
5,211,940 Transparent liquid oral composition 18 1992
 
Carter-Wallace, Inc. (1)
5,462,966 Methods for the prevention and control of cellular damage resulting from coronary artery occlusion-reperfusion 8 1993
 
DAIICHI PHARMACEUTICAL CO., LTD. (1)
5,480,888 Inhibitor for restenosis after percutaneous coronary arterioplasty 21 1994
 
CEDARS-SINAI MEDICAL CENTER (4)
5,112,305 Catheter device for intramural delivery of therapeutic agents 184 1990
5,242,397 Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty 90 1992
5,562,922 Drug incorporating and release polymeric coating for bioprosthesis 147 1995
5,900,246 Drug incorporating and releasing polymeric coating for bioprosthesis 95 1995
 
Alkermes Controlled Therapeutics, Inc. (1)
* 5,413,797 Controlled release ACTH containing microspheres 53 1994
 
VENTION MEDICAL ADVANCED COMPONENTS, INC. (2)
5,282,785 Drug delivery apparatus and method 290 1992
5,458,568 Porous balloon for selective dilatation and drug delivery 276 1993
 
KYOWA HAKKO KOGYO CO., LTD. (3)
4,555,402 Physiologically active substance K-252, process for producing same and pharmaceutical composition containing same 26 1984
4,935,415 UCN-01 and process for production thereof 24 1987
5,344,926 Process for producing staurosporine derivatives 30 1993
 
Gared Corporation (1)
4,320,896 Shock-absorbing assembly for basketball backboard 40 1980
 
GILEAD SCIENCES, INC. (2)
5,731,144 High affinity TGF.beta. nucleic acid ligands 19 1995
5,731,424 High affinity TGF.beta. nucleic acid ligands and inhibitors 40 1995
 
Advanced Surface Technology, Inc. (1)
5,700,559 Durable hydrophilic surface coatings 118 1994
 
BOEHRINGER MANNHEIM GMBH (1)
5,114,847 Process for the production of permanently culturable animal and human cell lines and the use thereof 11 1990
 
United States Surgical Corporation (3)
4,916,193 Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides 208 1988
4,990,158 Synthetic semiabsorbable tubular prosthesis 63 1989
5,185,408 Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides 110 1991
 
BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION (2)
5,393,772 Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation 61 1993
5,453,436 Treatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine compounds 49 1994
 
Glycomed Incorporated (3)
5,032,679 Heparin fragments as inhibitors of smooth muscle cell proliferation 62 1989
5,280,016 Non-anticoagulant heparin derivatives 51 1991
5,380,716 Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation 54 1992
 
NOVARTIS CORPORATION (1)
5,093,330 Staurosporine derivatives substituted at methylamino nitrogen 59 1991
 
The Board of Regents of the University of Oklahoma (7)
4,442,119 Cyclopropyl analogs as estrogenic and anti-fertility agents 36 1982
4,879,315 Cyclopropyl analogs as anti-estrogenic, anti-tumor and female fertility agents 43 1987
5,015,666 Triarylcyclopropanes as antiestrogens and antitumor agents 36 1989
5,098,903 Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents 48 1989
5,324,736 Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents 31 1993
5,658,927 Diphenylcyclopropyl analogs 12 1995
5,658,951 Diphenylcyclopropyl analogs 11 1995
 
AMAG PHARMACEUTICALS, INC. (1)
5,314,679 Vascular magnetic resonance imaging agent comprising nanoparticles 53 1992
 
LATHAM, DANIEL W. (1)
5,464,650 Intravascular stent and method 885 1993
 
La Jolla Cancer Research Foundation (2)
5,453,492 60 kDa transforming growth factor-.beta.-binding protein and its use to detect or purify TGF-.beta. 56 1993
5,705,609 Decorin fragments inhibiting cell regulatory factors 21 1995
 
DERMAGENESIS, LLC (1)
5,290,271 Surgical implant and method for controlled release of chemotherapeutic agents 292 1993
 
Ciba Specialty Chemicals Corporation (1)
5,354,801 Process for producing small polymer phase droplet microemulsions by multistep aqueous phase addition 31 1993
 
HOFFMANN-LA ROCHE INC. (2)
4,317,915 Novel thiophene derivatives 17 1980
4,428,963 Novel thiophene derivatives 14 1983
 
INNOVATIONAL HOLDINGS LLC (3)
6,241,762 Expandable medical device with ductile hinges 281 1998
6,562,065 Expandable medical device with beneficial agent delivery mechanism 114 2000
6,764,507 Expandable medical device with improved spatial distribution 88 2001
 
HANSON, STEPHEN (1)
4,687,482 Vascular prosthesis 59 1984
 
YALE UNIVERSITY (2)
4,990,538 Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs 57 1989
5,354,774 Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light 44 1992
 
BRISTOL-MYERS SQUIBB COMPANY (4)
5,015,578 BMY-41950 antitumor antibiotic 28 1990
5,073,633 BMY-41950 antitumor antibiotic 29 1990
5,304,541 Methods using novel chimeric transforming growth factor-.beta.1/.beta.2 37 1991
5,444,164 TGF-.beta. induced gene 36 1992
 
Cornell Research Foundation, Inc. (1)
4,629,694 Detecting and distinguishing between plasminogen activators 18 1983
 
GENZYME CORPORATION (4)
5,213,580 Biodegradable polymeric endoluminal sealing process 298 1992
5,328,471 Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens 568 1993
5,662,712 Apparatus for intraluminal photothermoforming 124 1995
5,749,915 Polymeric endoluminal paving process 91 1995
 
FOREST LABORATORIES, INC. (1)
4,389,393 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose 291 1982
 
Bayer Aktiengesellschaft (1)
5,008,279 Circulation-active fluoromethoxyphenyl dihydropyridine compounds 13 1988
 
EXPANDABLE GRAFTS PARTNERSHIP, A TX. GENERAL PARTNERSHIP (1)
4,776,337 Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft 1306 1986
 
EXPANDABLE GRAFTS PARTNERSHIP, 8000 I.H. 10 WEST, STE. 1265, SAN ANTONIO, TX A GENERAL PARTNERSHIP OF TX. (1)
4,733,665 Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft 2567 1985
 
The Trustees of the University of Pennsylvania (2)
5,075,321 Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes 101 1988
5,580,898 Method of stabilizing microtubules 14 1994
 
BIOGEN IDEC MA INC. (1)
5,240,913 Inhibitors of thrombin 29 1991
 
ABRAXIS BIOSCIENCE, LLC (1)
5,512,268 Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof 109 1995
 
SUNNYBROOK HEALTH SCIENCES CENTRE (1)
6,001,622 Integrin-linked kinase and its use 24 1998
 
Oncogen (2)
5,221,620 Cloning and expression of transforming growth factor .beta.2 40 1989
5,340,925 Normal human growth regulatory receptor for TGF-.beta. 32 1992
 
BIOGAL GYOGYSZERGYAR RT. (1)
5,037,641 Beauty preparations having anti-fading effect and a process for preparing the same 9 1988
 
International Copper Research Association (3)
4,757,059 Method for treating convulsions and epilepsy with organic copper compounds 17 1986
4,758,554 Method for treating convulsions and epilepsy with organic copper compounds 11 1986
4,758,555 Method for treating convulsions and epilepsy with organic copper compounds 9 1986
 
KOREA ATOMIC ENERGY RESEARCH INSTITUTE (1)
6,152,869 Radioactive stent and process for preparation thereof 36 1998
 
LUDWIG INSTITUTE FOR CANCER RESEARCH (4)
5,280,109 Isolated, large latent complexes of TGF-.beta.2 and TGF-.beta.3, and new binding protein for latent form TGF-.beta.1, TGF-.beta.2 and TGF-.beta.3 LTBP-2 33 1992
5,346,993 Isolated, large latent complexes of TGF-.beta.2 and TGF-.beta.3, and new binding protein for latent form TGF-.beta.1, TGF-.beta.2 and TGF-.beta.3 LTBP-2 30 1993
5,578,703 Substantially pure receptor like TFG-.beta.1 binding molecules 14 1994
5,731,200 Isolated nucleic acid encoding receptor-like TGF-.beta.1 binding protein 13 1995
 
ALZA CORPORATION (1)
4,786,500 Programmable agent delivery system 41 1986
 
SCHERING CORPORATION (1)
5,238,950 Inhibitors of platelet-derived growth factor 65 1991
 
Zynaxis Technologies, Inc. (1)
5,667,764 Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles 85 1992
 
CATHCO, INC. (1)
5,180,376 Non-buckling thin-walled sheath for the percutaneous insertion of intraluminal catheters 154 1990
 
The Scripps Research Institute (1)
4,929,602 Method of inhibiting platelet dependent arterial thrombosis 53 1988
 
SCHERING AKTIENGESELLSCHAFT (2)
4,310,523 Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate 27 1980
5,316,766 Thrombosis treatment with fibrinolytics and prostacyclins 30 1990
 
MEDTRONIC, INC. (26)
4,886,062 Intravascular radially expandable stent and method of implant 1433 1987
5,102,402 Releasable coatings on balloon catheters 386 1991
5,282,823 Intravascular radially expandable stent 517 1992
5,607,463 Intravascular medical device 360 1993
5,545,208 Intralumenal drug eluting prosthesis 353 1993
5,429,618 Thromboresistant articles 71 1994
5,510,077 Method of making an intraluminal stent 129 1994
5,571,166 Method of making an intraluminal stent 197 1994
5,591,224 Bioelastomeric stent 283 1994
5,599,352 Method of making a drug eluting stent 207 1994
5,554,182 Method for preventing restenosis 194 1995
5,591,227 Drug eluting stent 298 1995
5,697,967 Drug eluting stent 324 1995
5,800,507 Intraluminal stent 130 1995
5,837,008 Intravascular stent and method 376 1995
5,849,034 Intraluminal stent 77 1995
5,624,411 Intravascular stent and method 579 1995
5,679,400 Intravascular stent and method 553 1995
5,776,184 Intravasoular stent and method 420 1996
5,824,048 Method for delivering a therapeutic substance to a body lumen 506 1996
5,779,732 Method and apparatus for implanting a film with an exandable stent 62 1997
6,106,454 Medical device for delivering localized radiation 86 1997
6,203,536 Medical device for delivering a therapeutic substance and method therefor 74 1997
6,099,499 Device for in vivo radiation delivery and method for delivery 32 1998
6,013,099 Medical device for delivering a water-insoluble therapeutic salt or substance 109 1998
6,187,370 Medical device for delivering a therapeutic substance and method therefor 47 1999
 
ZymoGenetics, Inc. (3)
5,280,040 Methods for reducing bone loss using centchroman derivatives 65 1993
5,451,603 3,4-diarylchromans for treatment of dermatitis 12 1993
5,480,903 3,4-diarylchromans for inhibiting calmodulin activity 13 1994
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (7)
4,485,096 Tissue-equivalent and method for preparation thereof 203 1982
4,485,097 Bone-equivalent and method for preparation thereof 231 1983
5,114,719 Extended drug delivery of small, water-soluble molecules 67 1989
5,175,235 Branched polyanhydrides 50 1990
5,545,409 Delivery system for controlled release of bioactive factors 42 1994
5,567,417 Method for inhibiting angiogenesis using heparinase 47 1995
5,797,898 Microchip drug delivery devices 403 1996
 
Research Triangle Institute Duke University (1)
5,436,243 Aminoanthraquinone derivatives to combat multidrug resistance 43 1993
 
Washington Research Foundation (2)
4,656,083 Plasma gas discharge treatment for improving the biocompatibility of biomaterials 197 1985
5,034,265 Plasma gas discharge treatment for improving the compatibility of biomaterials 65 1989
 
ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (2)
* 5,171,217 Method for delivery of smooth muscle cell inhibitors 309 1991
5,116,864 Method for preventing restenosis following reconfiguration of body vessels 128 1991
 
S.K.Y. POLYMERS, INC. (1)
5,688,855 Thin film hydrophilic coatings 66 1995
 
ASTRAZENECA UK LIMITED (1)
4,536,516 Alkene derivatives 53 1984
 
STOLLE MILK BIOLOGICS, INC. (1)
RE33403 Method for treating disorders of the vascular and pulmonary systems 21 1989
 
ASTRAZENECA AB (1)
6,555,138 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances 6 1999
 
TEKMIRA PHARMACEUTICALS CORPORATION (1)
5,478,860 Stable microemulsions for hydrophobic compound delivery 56 1993
 
The General Hospital Corporation (1)
5,538,892 Nucleic acids encoding a TGF-.beta. type 1 receptor 42 1993
 
ST. JUDE MEDICAL, INC. (1)
6,491,617 Medical devices that resist restenosis 31 1999
 
CHILDREN'S MEDICAL CENTER CORPORATION (3)
4,391,797 Systems for the controlled release of macromolecules 122 1981
4,753,652 Biomaterial implants which resist calcification 278 1986
5,994,388 Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis 5 1998
 
TRUSTEES OF TUFTS COLLEGE (1)
4,859,585 In-vitro methods for identifying compositions which are agonists and antagonists of estrogens 57 1986
 
ZAMBON GROUP S.P.A. (1)
5,468,746 Compounds active on the cardiovascular system 33 1991
 
J.R.J. SORENSON CORP. (3)
4,440,754 Anti-inflammatory and anti-ulcer compounds and process 27 1980
4,999,347 Analgesic method 27 1989
5,082,834 Anti-inflammatory and anti-ulcer compounds and process 10 1990
 
NEXSTAR PHARMACEUTICALS, INC. (1)
5,441,947 Methods of inhibiting vascular restenosis 57 1993
 
YOSHIDA, ROBERT (1)
5,492,895 Inhibitors of thrombosis 49 1994
 
IsoStent, Inc. (1)
5,722,984 Antithrombogenic radioactive coating for an intravascular stent 209 1996
 
EGIS GYOGYSZERGYAR RT. (1)
5,543,155 Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same 33 1994
 
Bioseal, LLC (1)
5,660,873 Coating intraluminal stents 44 1994
 
Sterling Drug Inc. (1)
5,145,684 Surface modified drug nanoparticles 654 1991
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
5,364,632 Medicinal emulsions 112 1993
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (1)
4,826,672 Astatinated organic compounds 37 1985
 
Harbor Medical Devices, Inc. (2)
5,447,724 Medical device polymer 467 1993
5,569,463 Medical device polymer 366 1995
 
SYNTEX (U.S.A.) INC. (2)
4,675,189 Microencapsulation of water soluble active polypeptides 323 1985
4,962,091 Controlled release of macromolecular polypeptides 215 1986
 
PDT Systems, Inc. (2)
5,429,634 Biogenic implant for drug delivery and method 165 1993
5,419,760 Medicament dispensing stent for prevention of restenosis of a blood vessel 259 1994
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (5)
4,984,594 Vacuum method for removing soil contamination utilizing surface electrical heating 356 1989
5,219,548 High affinity halogenated-tamoxifen derivatives and uses thereof 41 1990
5,238,714 Efficient microcapsule preparation and method of use 72 1990
5,192,525 High affinity tamoxifen derivatives and uses thereof 64 1991
5,656,450 Activation of latent transforming growth factor .beta. by matrix vesicles 26 1994
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (11)
* 4,942,184 Water soluble, antineoplastic derivatives of taxol 162 1988
5,405,919 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders 129 1992
5,656,587 Promotion of cell proliferation by use of transforming growth factor beta (TGF-.beta.) 37 1993
5,525,357 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same 116 1993
5,705,477 Compositions of transforming growth factor .beta.(TGF-.beta.) which promotes wound healing and methods for their use 27 1994
5,632,981 Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same 58 1994
5,616,608 Method of treating atherosclerosis or restenosis using microtubule stabilizing agent 206 1996
6,429,232 Method of treating atherosclerosis or restenosis using microtubule stabilizing agent 56 1997
6,200,558 Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same 35 1997
6,403,635 Method of treating atherosclerosis or restenosis using microtubule stabilizing agent 65 2000
6,379,660 Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same 34 2000
 
PFIZER INC. (2)
4,282,246 Antidiabetic furancarboxylic and thiphenecarboxylic acids 13 1980
5,441,986 Estrogen agonists as remedies for prostate and cardiovascular diseases 34 1994
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
5,824,647 Chemotactic wound healing peptides 18 1995
 
Eli Lilly and Company (71)
4,323,707 Antifertility compounds 22 1980
4,380,635 Synthesis of acylated benzothiophenes 262 1981
4,418,068 Antiestrogenic and antiandrugenic benzothiophenes 387 1981
5,270,047 Local delivery of dipyridamole for the treatment of proliferative diseases 40 1991
5,482,949 Sulfonate derivatives of 3-aroylbenzo[b]thiophenes 53 1993
5,445,941 Method for screening anti-osteoporosis agents 38 1993
5,391,557 Methods for the treatment of peri-menopausal syndrome 44 1993
5,418,252 Method for inhibiting cartilage degradation 28 1993
5,441,964 Methods for inhibiting bone loss using substituted benzothiophene 37 1993
5,457,113 Methods for inhibiting vascular smooth muscle cell proliferation and restinosis 97 1993
5,457,116 Methods of inhibiting uterine fibrosis 32 1993
5,461,065 Methods for inhibiting endometriosis 26 1993
5,482,950 Methods for lowering serum cholesterol 16 1993
5,480,904 Methods for inhibiting uterine fibrosis 17 1993
5,389,670 Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder 39 1993
5,439,923 Method of inhibiting seborrhea and acne 27 1993
5,439,931 Method for increasing libido in post-menopausal women 27 1993
5,441,965 Methods of inhibiting thrombin 32 1993
5,441,966 Methods of inhibiting Turner's syndrome 24 1993
5,446,053 Methods of inhibiting dysfunctional uterine bleeding 28 1993
5,447,941 Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes 29 1993
5,451,589 Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism 20 1993
5,451,590 Methods of inhibiting sexual precocity 20 1993
5,461,064 Methods of inhibiting atrophy of the skin and vagina 24 1993
5,462,949 Methods of inhibiting fertility in women 24 1993
5,462,950 Methods of treating menstrual symptoms and compositions therefore 33 1993
5,492,927 Non-peptide tachykinin receptor antagonists to treat allergy 37 1993
5,521,198 Methods of inhibiting autoimmune diseases 19 1993
5,552,415 Method of inhibiting Alzheimer's Disease 34 1993
5,574,047 Methods of inhibiting imperfect tissue repair 14 1993
5,393,763 Methods for inhibiting bone loss 95 1994
5,478,847 Methods of use for inhibiting bone loss and lowering serum cholesterol 29 1994
5,384,332 Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives 58 1994
5,426,123 Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives 23 1994
5,455,275 Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives 37 1994
5,466,810 2-amino-3-aroyl-benzo[.beta.]thiophenes and methods for preparing and using same to produce 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)-benzoyl]benzo[.beta.]thiophenes 23 1994
5,434,166 Methods of inhibiting demyelinating and desmyelinating diseases 27 1994
5,496,828 Methods of inhibiting ulcerative mucositis 25 1994
5,457,117 Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride 39 1994
5,453,442 Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease 28 1994
5,567,713 Hypoglycemic agents 18 1995
5,489,587 Benzofurans used to inhibit bone loss 21 1995
5,571,808 Method for treating smoking-related bone loss 10 1995
5,484,808 Methods of inhibiting cell-cell adhesion 33 1995
5,510,370 Parathyroid hormone and raloxifene for increasing bone mass 66 1995
5,525,624 Non-peptide tachykinin receptor antagonists to treat psycological disorder 22 1995
5,686,467 Methods of inhibiting imperfect tissue repair 12 1995
5,686,476 Methods of inhibiting Alzheimer's Disease 24 1995
5,610,166 Methods for inhibiting angiogenesis 17 1995
5,563,054 Process for preparation of benzo[B]thiophene glucuronides 14 1995
5,462,937 Methods for inhibiting vascular smooth muscle cell proliferation and restinosis 32 1995
5,492,926 Methods for inhibiting vascular smooth muscle cell proliferation and restinosis 20 1995
5,496,851 Methods of inhibiting cell-cell adhesion 18 1995
5,508,292 Methods of inhibiting thrombin 22 1995
5,534,527 Methods for inhibiting bone loss by treating with aroylbenzothiophenes and estrogen 28 1995
5,610,168 Methods of use for inhibiting bone loss and lowering serum cholesterol 13 1995
5,641,790 Methods of use for inhibiting bone loss and lowering serum cholesterol 25 1995
5,688,813 Methods of inhibiting thrombin 12 1995
5,484,798 Benzothiopene compounds, compositions, and method of inhibiting restenosis 35 1995
5,492,921 Benzothiophene compounds, compositions, and methods for inhibiting aortal smooth muscle proliferation 11 1995
5,484,795 Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting restenosis 40 1995
5,484,796 Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting aortal smooth muscle cell proliferation 14 1995
5,484,797 Naphthly compounds, intermediates, processes, compositions, and method for inhibiting endometrosis 18 1995
5,622,975 Methods for inhibiting vascular smooth muscle cell migration 27 1995
5,492,922 Benzothiophene compounds intermediate compositions and methods for inhibiting aortal smooth muscle proliferation 46 1995
5,521,172 Methods for lowering serum cholesterol 7 1995
5,552,433 Method for lowering serum cholesterol 8 1995
5,556,876 Methods for lowering serum cholesterol 5 1995
5,652,259 Methods of inhibiting Alzheimer's disease 11 1996
5,726,186 Pentacyclic compounds, intermediates, processes, compositions, and methods 10 1996
5,747,510 Pharmaceutical unit dosage formulations 20 1997
 
NOVO PHARMACEUTICAL CORPORATION (1)
5,189,046 Protein kinase C modulators 45 1991
 
ORION-YHTYMA OY (1)
5,491,173 Tri-phenyl alkene derivatives and their preparation and use 49 1994
 
FIDIA S.P.A. (1)
5,416,205 New esters of alginic acid 15 1993
 
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (1)
5,126,348 Bioavailability enhancers 26 1989
 
JOHNSON MATTHEY, INC. (1)
5,100,885 Copper radiosensitizers 19 1989
 
CENTOCOR, INC. (1)
5,026,537 Methods for imaging atherosclerotic plaque 54 1989
 
MERCK SHARP & DOHME CORP. (1)
5,441,734 Metal-interferon-alpha crystals 44 1993
 
Elizabeth-Hata International, Inc. (1)
5,391,378 Two-part medicinal tablet and method of manufacture 33 1993
 
CORDIS CORPORATION (12)
4,739,762 Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft 1224 1986
5,102,417 Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft 949 1988
4,994,071 Bifurcating stent apparatus and method 1024 1989
5,049,132 Balloon catheter for delivering therapeutic agents 406 1990
5,195,984 Expandable intraluminal graft 699 1991
5,213,576 Therapeutic porous balloon catheter 315 1991
6,146,358 Method and apparatus for delivery of therapeutic agent 198 1992
5,902,332 Expandable intraluminal graft 206 1992
5,486,357 Radiofrequency plasma biocompatibility treatment of inside surfaces 33 1993
5,356,433 Biocompatible metal surfaces 358 1993
5,863,285 Balloon catheter with radioactive means 76 1997
2004/0236,416 Increased biocompatibility of implantable medical devices 68 2004
 
The Regents of the University of California (3)
5,342,926 Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport 15 1993
5,407,658 Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport 16 1994
5,583,153 Use of taxol in the treatment of rheumatoid arthritis 41 1994
 
Health Maintenance Programs, Inc. (1)
5,326,757 Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty 82 1993
 
CONSIGLIO NAZIONALE DELLE RICERCHE (1)
4,767,758 Pharmaceutical compositions containing thiophene compounds, and new thiophene compounds 13 1987
 
QUADRA LOGIC TECHNOLOGIES INC. (1)
5,422,362 Method to inhibit restenosis 68 1993
 
University of Washington (1)
5,521,191 Method for treatment of arterial stenosis 21 1994
 
OLYMPUS OPTICAL CO., LTD. (1)
5,318,779 Drug-impregnated ceramic 31 1990
 
ORION CORPORATION (3)
4,696,949 Novel tri-phenyl alkane and alkene derivatives and their preparation and use 54 1986
4,996,225 Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses 33 1989
5,605,700 Topical administration of toremifene and its metabolites 28 1994
 
DUKE UNIVERSITY (1)
5,527,337 Bioabsorbable stent and method of making the same 459 1994
 
Genentech, Inc. (8)
5,108,989 Method of predisposing mammals to accelerated tissue repair 66 1990
5,208,019 Use of gamma-interferon for the treatment of vascular stenosis 40 1991
5,118,791 Biologically active polypeptides based on transforming growth factor-.beta. 33 1991
5,216,126 Receptor polypeptides and their production and uses 81 1991
5,166,191 Use of relaxin in cardiovascular therapy 35 1991
5,268,455 Process for making biologically active polypeptides based on transforming growth factor-.beta.sequences 20 1992
5,284,763 Nucleic acid encoding TGF-.beta. and its uses 37 1992
5,482,851 Nucleic acid encoding TGF-.beta. and its uses 8 1993
 
HEMAGEN/PFC A LIMITED PARTNERSHIP OF CALIFORNIA (1)
5,304,325 Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use 48 1991
 
BIOCOMPATIBLES UK LIMITED (1)
5,496,581 Polymeric coating 26 1993
 
HERITAGE TECHNOLOGIES, LLC (1)
5,451,414 Micronutrient supplement 10 1994
 
ENDORECHERCHE, A CANADIAN CORPORATION (1)
5,395,842 Anti-estrogenic compounds and compositions 115 1991
 
ENDOTEX INTERNATIONAL SYSTEMS, INC. (1)
5,824,054 Coiled sheet graft stent and methods of making and use 186 1997
 
Abbott Cardiovascular Systems Inc. (2)
5,514,154 Expandable stents 752 1994
6,656,216 Composite stent with regioselective material 213 2001
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (2)
5,260,224 Therapeutic uses of actin-binding compounds 38 1991
5,358,844 Preservation of blood platelets 43 1993
 
MATRIX PHARMACEUTICAL, INC. (1)
5,597,578 TGF-.beta. protein compositions for inhibition of cell proliferation 37 1994
 
VALEANT INTERNATIONAL BERMUDA (1)
5,439,689 Diltiazem formulation 58 1993
 
SRI INTERNATIONAL (1)
5,354,562 Process for preparing micronized polypeptide drugs 129 1993
 
Zinpro Corporation (2)
4,900,561 Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements 29 1989
4,956,188 Copper complexes with alpha hydroxy organic acids and their use as nutritional supplements 29 1989
 
Shepherd Patents S.A. (1)
4,954,126 Prosthesis comprising an expansible or contractile tubular body 830 1989
 
ACDS TECHNOLOGIES, INC. (1)
5,424,331 Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis 84 1994
 
ANGIOTECH PHARMACEUTICALS, INC. (2)
6,110,483 Adherent, flexible hydrogel and medicated coatings 351 1997
6,544,544 Anti-angiogenic compositions and methods of use 168 2001
 
PHARMETRIX, MENLO PARK (1)
* 4,919,939 Periodontal disease treatment system 190 1988
 
ANGIOTECH BIOCOATINGS CORP. (1)
5,716,981 Anti-angiogenic compositions and methods of use 795 1995
 
ALKERMES PHARMA IRELAND LIMITED (1)
5,346,702 Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization 115 1992
 
NIPPON KAYAKU KABUSHIKI KAISHA (1)
5,296,492 Certain chroman derivatives useful for treating symptoms caused by contraction of smooth muscles, circulatory diseases or epilepsy 28 1992
 
CARDIOPULMONICS, A CORP OF UTAH (1)
5,338,770 Gas permeable thrombo-resistant coatings and methods of manufacture 67 1990
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (1)
4,491,574 Reduction of high dose aspirin toxicity by dietary vitamin A 26 1983
 
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (2)
5,362,424 Microencapsulation for controlled oral drug delivery system 66 1991
5,415,619 Method of manufacturing a vascular graft impregnated with polysaccharide derivatives 54 1993
 
BAYLOR COLLEGE OF MEDICINE (1)
5,216,024 Cell growth inhibitors and methods of treating cancer and cell proliferative diseases 26 1988
 
INTERMEDICAT GMBH, GERLISWILSTRASSE 74, CH-6020 EMMENBRUCKE, SWITZERLAND, (1)
4,784,659 Vessel and prosthesis impregnated with diisocyanate crosslinked gelatin 96 1987
 
NoeRx Corporation (1)
* 6,074,659 Therapeutic inhibitor of vascular smooth muscle cells 253 1998
 
WYETH (15)
5,288,711 Method of treating hyperproliferative vascular disease 169 1992
5,252,579 Macrocyclic immunomodulators 94 1993
5,302,584 Carbamates of rapamycin 106 1993
5,387,680 C-22 ring stabilized rapamycin derivatives 45 1993
5,411,967 Carbamates of rapamycin 60 1994
5,504,091 Biotin esters of rapamycin 71 1994
5,516,781 Method of treating restenosis with rapamycin 222 1994
5,491,159 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-oxazoles as anti-atherosclerotic agents 19 1994
5,498,775 Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation 33 1994
5,563,145 Rapamycin 42-oximes and hydroxylamines 67 1994
5,525,610 42-Epi-rapamycin and pharmaceutical compositions thereof 55 1995
5,563,146 Method of treating hyperproliferative vascular disease 134 1995
5,646,160 Method of treating hyperproliferative vascular disease with rapamycin and mycophenolic acid 103 1995
5,665,728 Method of treating hyperproliferative vascular disease 88 1995
5,677,295 Rapamycin 42-oximes and hydroxylamines 9 1996
 
SYNGENTA CROP PROTECTION, INC. (1)
5,332,584 Microcapsules 44 1991
 
Endorecherche, Inc. (1)
5,393,785 Therapeutic antiestrogens 37 1992
 
Celtrix Pharmaceuticals, Inc. (4)
5,571,714 Monoclonal antibodies which bind both transforming growth factors .beta.1 and .beta.2 and methods of use 55 1991
5,462,925 Transforming growth factor .beta.2,3 18 1992
5,658,883 Biologically active TGF-.beta.1 peptides 8 1995
5,767,079 Method of treating ophthalmic disorders using TGF -.beta. 53 1996
 
BOSTON SCIENTIFIC SCIMED, INC. (33)
4,994,033 Intravascular drug delivery dilatation catheter 450 1989
5,009,659 Fiber tip atherectomy catheter 221 1989
5,064,435 Self-expanding prosthesis having stable axial length 1156 1990
5,222,971 Temporary stent and methods for use and manufacture 421 1990
5,304,121 Drug delivery system making use of a hydrogel polymer coating 659 1991
5,197,977 Drug delivery collagen-impregnated synthetic vascular graft 396 1992
5,234,456 Hydrophilic stent 563 1992
5,449,382 Minimally invasive bioactivated endoprosthesis for vessel repair 430 1994
6,515,009 Therapeutic inhibitor of vascular smooth muscle cells 90 1995
5,811,447 Therapeutic inhibitor of vascular smooth muscle cells 216 1995
5,578,075 Minimally invasive bioactivated endoprosthesis for vessel repair 282 1995
6,171,609 Therapeutic inhibitor of vascular smooth muscle cells 211 1995
5,837,313 Drug release stent coating process 762 1996
6,120,536 Medical devices with long term non-thrombogenic coatings 665 1996
* 5,733,925 Therapeutic inhibitor of vascular smooth muscle cells 466 1996
5,735,897 Intravascular stent pump 352 1997
* 5,981,568 Therapeutic inhibitor of vascular smooth muscle cells 328 1997
6,306,421 Therapeutic inhibitor of vascular smooth muscle cells 103 1997
5,980,972 Method of applying drug-release coatings 519 1997
6,099,562 Drug coating with topcoat 618 1997
2002/0032,477 DRUG RELEASE COATED STENT 113 1998
6,129,757 Implantable members for receiving therapeutically useful compositions 32 1998
6,358,989 Therapeutic inhibitor of vascular smooth muscle cells 54 1999
* 6,268,390 Therapeutic inhibitor of vascular smooth muscle cells 93 1999
6,783,543 Intravascular stent with increasing coating retaining capacity 142 2001
6,491,938 Therapeutic inhibitor of vascular smooth muscle cells 109 2001
6,599,928 Therapeutic inhibitor of vascular smooth muscle cells 58 2001
2002/0013,275 Therapeutic inhibitor of vascular smooth muscle cells 22 2001
6,569,441 Therapeutic inhibitor of vascular smooth muscle cells 101 2001
2002/0091,433 Drug release coated stent 251 2001
* 6,663,881 Therapeutic inhibitor of vascular smooth muscle cells 82 2001
6,656,162 Implantable drug delivery stents 230 2002
6,720,350 Therapeutic inhibitor of vascular smooth muscle cells 86 2002
 
BOSTON SCIENTIFIC CORPORATION (2)
4,762,129 Dilatation catheter 666 1986
4,922,905 Dilatation catheter 654 1988
 
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (2)
5,216,115 Polyarylate containing derivatives of the natural amino acid L-tyrosine 76 1992
5,877,224 Polymeric drug formulations 300 1995
 
WYETH LLC (1)
5,362,718 Rapamycin hydroxyesters 162 1994
 
LUDWIG INSTITUTE FOR CANCER RESEARCH A CORP. OF NEW YORK (1)
5,229,495 Substantially pure receptor like TGF-.beta. 1 binding molecules and uses thereof 48 1991
 
The United States of America as represented by the Secretary of Agriculture (2)
4,973,601 Control of insects by fungal tremorgenic mycotoxins 17 1988
5,019,504 Production of taxol or taxol-like compounds in cell culture 79 1989
 
MEDINOL LTD. (5)
5,733,303 Flexible expandable stent 391 1995
5,843,120 Flexible-expandable stent 268 1997
5,972,018 Flexible expandable stent 168 1998
6,461,381 Flexible expandable stent 64 1999
6,443,982 Flexible expandable stent 81 2000
 
SCIMED LIFE SYSTEMS, INC. (3)
5,464,450 Biodegradable drug delivery vascular stent 304 1994
5,551,954 Biodegradable drug delivery vascular stent 318 1994
5,500,013 Biodegradable drug delivery vascular stent 373 1995
 
MedInnovations, Inc. (1)
4,768,507 Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis 725 1987
 
Innerdyne, Inc. (2)
5,262,451 Multifunctional thrombo-resistant coatings and methods of manufacture 67 1988
5,182,317 Multifunctional thrombo-resistant coatings and methods of manufacture 108 1991
 
Quanam Medical Corporation (1)
6,168,619 Intravascular stent having a coaxial polymer member and end sleeves 139 1998
 
VENTECH RESEARCH, INC. (1)
5,232,911 Mixture of a non-covalent heterodimer complex and a basic amphiphatic peptide as cytotoxic agent 24 1991
 
The Trustees of Columbia University in the City of New York (2)
4,959,355 Method of inhibiting osmotic water flow 15 1987
5,019,096 Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same 638 1988
 
ENERGY, UNITED STATES DEPARTMENT OF (1)
5,185,260 Method for distinguishing normal and transformed cells using G1 kinase inhibitors 48 1991
 
KLINGE PHARMA GMBH (2)
5,047,431 1,1,2-triphenylbut-1-ene derivatives 72 1990
5,254,594 Remedies for bone diseases 72 1992
 
The Hope Heart Institute (1)
5,401,730 Method for reducing platelet aggregation 38 1993
 
SULZER CARBOMEDICS INC. (1)
4,689,046 Heart valve prosthesis 47 1985
 
N.V. ORGANON (1)
5,496,557 Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances 43 1993
 
EMORY UNIVERSITY (3)
5,399,352 Device for local drug delivery and methods for using the same 68 1993
5,383,928 Stent sheath for local drug delivery 411 1993
5,523,092 Device for local drug delivery and methods for using the same 172 1994
 
NITROMED, INC. (1)
6,087,479 Localized use of nitric oxide-adducts to prevent internal tissue damage 101 1995
 
OSI PHARMACEUTICALS, INC. (2)
5,262,319 Method for obtaining bone marrow free of tumor cells using transforming growth factor .beta.3 28 1990
5,635,489 Methods of prevention of oral mucositis with transforming growth factor .beta. 15 1995
 
MED INSTITUTE, INC. (5)
5,380,299 Thrombolytic treated intravascular medical device 445 1993
5,609,629 Coated implantable medical device 764 1995
6,096,070 Coated implantable medical device 924 1996
5,824,049 Coated implantable medical device 886 1996
5,873,904 Silver implantable medical device 868 1997
 
INFIGEN, INC. (1)
4,994,384 Multiplying bovine embryos 59 1987
 
IMPERIAL CHEMICAL INDUSTRIES PLC (1)
4,307,111 1-Hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives 29 1980
 
CORVITA CORPORATION (2)
5,092,877 Radially expandable endoprosthesis 416 1990
5,226,913 Method of making a radially expandable prosthesis 401 1992
 
PHARMACIA AB (1)
5,576,345 Method and means for inhibiting posterior capsule opacification 23 1996
 
ADVANCED BIO PROSTHETIC SURFACES, LTD. (1)
4,793,348 Balloon expandable vena cava filter to prevent migration of lower extremity venous clots into the pulmonary circulation 477 1986
 
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (1)
5,167,960 Hirudin-coated biocompatible substance 76 1988
 
INNOVENT, INC. (1)
5,420,243 Biologically active TGF-.beta.2 peptides 23 1993
 
Advanced Cardiovascular Systems, Inc. (20)
4,748,982 Reinforced balloon dilatation catheter with slitted exchange sleeve and method 712 1987
5,496,346 Reinforced balloon dilatation catheter with slitted exchange sleeve and method 387 1993
5,423,885 Stent capable of attachment within a body lumen 467 1993
5,443,458 Multilayered biodegradable stent and method of manufacture 385 1993
5,421,955 Expandable stents and method for making same 712 1994
5,629,077 Biodegradable mesh and film stent 294 1994
5,637,113 Polymer film for wrapping a stent structure 463 1994
5,605,696 Drug loaded polymeric material and method of manufacture 690 1995
5,632,840 Method of making metal reinforced polymer stent 254 1995
5,626,600 Reinforced balloon dilatation catheter with slitted exchange sleeve and method 176 1995
6,066,167 Expandable stents 117 1998
6,488,694 Stent delivery system 155 1999
6,527,789 Stent delivery system 109 1999
6,309,412 Expandable stents and method for making same 62 2000
6,395,326 Apparatus and method for depositing a coating onto a surface of a prosthesis 524 2000
6,432,133 Expandable stents and method for making same 94 2000
6,596,022 Expandable stents and method for making same 62 2001
6,485,511 Expandable stents and method for making same 64 2001
6,616,765 Apparatus and method for depositing a coating onto a surface of a prosthesis 246 2002
6,689,159 Expandable stents and method for making same 52 2003
 
Surface Genesis, Inc. (1)
5,643,580 Biocompatible coating, medical device using the same and methods 70 1994
 
ATI MEDICAL, INC. (2)
6,074,337 Combination radioactive and temperature self-regulating thermal seed implant for treating tumors 20 1998
6,497,647 Radiation and thermal energy source 26 2001
 
ADAPTIVE TECHNOLOGIES, INC. (1)
5,099,504 Thickness/density mesuring apparatus 13 1989
 
JAGOTEC AG (3)
5,639,738 Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs 23 1992
6,022,866 Use of hyaluronic acid and forms to prevent arterial restenosis 41 1995
5,990,095 Use of hyaluronic acid and forms to prevent arterial restenosis 16 1995
 
HOWARD FOUNDATION, THE (1)
6,086,910 Food supplements 30 1997
 
Blendax-Werke, R. Schneider GmbH & Co. (3)
4,332,791 Toothpaste active against plaque comprising a copper compound and a silica polishing agent 50 1981
4,339,429 Toothpaste active against plaque comprising a copper compound and a plastic polishing agent 42 1981
4,824,661 Composition for oral hygiene 31 1986
 
Whittier Institute for Diabetes and Endocrinology (1)
5,308,622 Treatment of vascular injury 60 1992
 
BROOKWOOD PHARMACEUTICALS, INC. (1)
5,407,609 Microencapsulation process and products therefrom 241 1993
 
ProCyte Corporation (3)
4,760,051 Use of GHL-Cu as a wound-healing and anti-inflammatory agent 54 1985
5,023,237 Methods and compositions for healing ulcers 40 1989
5,145,838 Methods and compositions for healing ulcers 24 1991
 
ONCOGEN, A WA CORP. (1)
5,120,535 Oncostatin M and novel compositions having anti-neoplastic activity 45 1987
 
SANOFI-AVENTIS DEUTSCHLAND GMBH (1)
5,519,042 Method of treating hyperproliferative vascular disease 38 1994
 
BETH ISRAEL HOSPITAL ASSOCIATION (3)
4,512,762 Method of treatment of atherosclerosis and a balloon catheter for same 261 1982
4,577,636 Method for diagnosis of atherosclerosis 87 1984
5,226,430 Method for angioplasty 140 1991
 
Kissei Pharmaceutical Co., Ltd. (1)
5,385,935 Method for the inhibition of restenosis associated with coronary intervention 39 1993
 
ESSELTE CORPORATION (1)
5,651,627 Nib conversion unit 23 1996
 
Millennium Pharmaceuticals, Inc. (1)
5,948,639 TGF-.beta. pathway genes 12 1997
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2)
5,283,257 Method of treating hyperproliferative vascular disease 107 1992
5,821,234 Inhibition of proliferation of vascular smooth muscle cell 27 1993
 
C. R. Bard, Inc. (1)
5,147,332 Multi-valve catheter for improved reliability 86 1991
 
SCHNEIDER (USA) INC. (1)
6,042,875 Drug-releasing coatings for medical devices 412 1999
 
BURROUGHS WELLCOME CO. (4)
5,208,238 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance 28 1992
5,346,897 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance 29 1992
5,364,843 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance 31 1992
5,395,610 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance 28 1993
 
LIFESHIELD SCIENCES LLC (1)
5,053,048 Thromboresistant coating 230 1990
 
Boehringer Mannheim Pharmaceuticals Corporation - SmithKline Beecham Corp., Ltd. Partnership No. 1 (1)
5,308,862 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation 58 1993
 
Goedecke Aktiengesellschaft (1)
5,043,335 Indolocarbazoles and the use thereof 67 1990
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 29, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 29, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00